Biopharmaceutical Stock Omeros (NASDAQ: OMER) Trades up over 30% on News

Category: Investment, Biotech

News about Omeros Corporation

Point Roberts, WA - January 10, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Omeros Corporation (NASDAQ: OMER). The stock is trading at $5.85, up 1.38 (30.87%) 2:31PM with a high of $5.90 following news it has identified compounds that interact selectively with each of GPR25, GPR32, GPR80, GPR135 and MAS1, bringing the total number of orphan G protein-coupled receptors (GPCRs) unlocked by Omeros to 23, representing 30 percent of the Class A orphan GPCRs.

The Company went on to report, "To date, the number of orphans unlocked by Omeros for drug development equals half of the total number of GPCRs currently targeted by more than 30 percent of all marketed drugs. There are approximately 120 orphan GPCRs and Omeros expects to unlock a large percentage of them, focusing first on Class A orphan GPCRs."

The stock has a 52-week range of $3.16 -$ 8.41.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Get biotech news and stock alerts

http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - Source - www.Investorideas.com

This news is published on the Investorideas.com Newswire and its syndicated partner network

News now!

Get Investorideas.com investor news and stock alerts
Free Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

TOP